Optimum’s clients are at the forefront of climate change and cancer research
This week showcased the diverse projects and research that Optimum’s clients are involved with. These included STORM Therapeutics’ groundbreaking research into METTL3, an exciting new target in cancer therapy that was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, the biggest oncology meeting in the world. In the same week, our client Novo Nordisk Foundation awarded a grant for crops that could reduce climate change, Vivet Therapeutics published more data on research into the rare condition Wilson Disease, and Alchemab secured a US$595,000 grant for Parkinson’s Disease research from The Michael J. Fox Foundation.
STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024
STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, announced on Monday that interim Phase 1 clinical data from its first-in-class lead product, STC-15, was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, US.
STC-15 was well tolerated, and clinical activity was observed across the pharmacologically active dose range in advanced cancer patients. Primary objectives were achieved allowing STORM to progress its combination studies with STC-15 and checkpoint inhibitors.
Resolution Therapeutics Announces New Breakthrough Clinical Data for Macrophage Cell Therapy in End Stage Liver Disease at EASL 2024.
Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company developing macrophage cell therapies to treat end-stage liver disease announced on Wednesday key data presentations with the University of Edinburgh at the EASL Congress 2024 held in Milan, Italy. Data demonstrated the significant potential of macrophage cell therapy as a treatment for advanced liver cirrhosis.
Vivet Therapeutics presents interim data on its Phase 1/2 GATEWAY trial for the Treatment of Wilson Disease at EASL Congress 2024
Vivet Therapeutics a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, on Thursday announced the presentation of interim data on its international Phase 1/2 GATEWAY trial, evaluating the safety, pharmacodynamics, and efficacy of its lead program, VTX-801 for the treatment of Wilson Disease (WD) at the EASL Congress 2024, held in Milan, Italy on 5th-8th June.
VTX-801, increased ceruloplasmin ferroxidase activity and improved liver histology, while also showing encouraging safety and tolerability with no serious adverse events reported.
Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation
Alchemab Therapeutics (Alchemab), an antibody discovery company identifying naturally occurring antibodies from individuals resilient to disease, on Thursday announced that it has been awarded a grant of US$595,000 by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support its Parkinson’s disease program. The grant will fund research into prostaglandin biology in Parkinson’s disease (PD), a potentially unique approach to treatment. Alchemab is researching the therapeutic effects of its resilient patient-derived antibody in PD.
New innovative crops could significantly reduce agriculture’s climate change impact and environmental footprint
The Novo Nordisk Foundation on Tuesday awarded a grant of up to $21.1 million to CIMMYT for a groundbreaking initiative to mitigate the environmental impact of agriculture, by developing new wheat varieties that are capable of reducing agriculture’s nitrogen footprint. The CropSustaiN initiative could have sweeping implications for global food security and environmental sustainability.
2nd episode of the Optimum Perspectives Podcast looks at AI in drug development
The regularly updated Optimum Perspectives Podcast is going from strength to strength and is now on its 22nd episode. Hit the subscribe button to catch the episodes as we publish them!
Two new episodes of Optimum TV went live this week – check out Xeltis’ CEO Eliane Schutte talk about how to “build” a new blood vessel – the natural way, and Amir Hefni, CEO of Resolution Therapeutics, on using cell therapy to revolutionise treatment of end-stage liver disease.
That’s all folks! We hope you are enjoying Optimum’s weekly round-ups; subscribe today so you never miss an edition.
